GlassScriptPhysician profile
Bridget O Leary
NPI 1215567995
$1,610.98
in general payments reported to CMS, 2019-2025
22 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.86 · 2022: $380 · 2023: $487 · 2024: $422 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.40 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $187.60 | 2022-2024 | Quviviq |
| Dexcom, INC. | $180.84 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $138.18 | 2022-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $123.82 | 2023 | |
| Xeris Pharmaceuticals, INC. | $61.00 | 2022-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $60.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.65 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Insulet Corporation | $46.84 | 2024-2025 | Omnipod |
| Amgen INC. | $45.93 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi Pasteur INC. | $36.11 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $32.56 | 2023-2024 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.46 | 2021-2023 | Jardiance |
| Pfizer INC. | $30.56 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $29.57 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.88 | 2023 | Austedo, Ajovy |
| Vanda Pharmaceuticals INC. | $25.54 | 2025 | Fanapt |
| Seqirus USA INC | $23.17 | 2025 | Flucelvax |
| Otsuka America Pharmaceutical, INC. | $20.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.81 | 2024 | Voquezna |
| Novo Nordisk INC | $15.98 | 2021 | |
| Medtronic, INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget O Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.